Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $185 to $194.
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $185 to $194.